First annual report of the Austrian CML registry

Wiener Klinische Wochenschrift

Volumn 122, Issue 19-20, 2010, Pages 558-566

  Schmidt, Stefan ^a   Wolf, Dominik ^a   Thaler, Josef ^b   Burgstaller, Sonja ^b   Linkesch, Wolfgang ^c   Petzer, Andreas ^d   Fridrik, Michael ^e   Lang, Alois ^f   Agis, Hermine ^g   Valent, Peter ^g   Krieger, Otto ^h   Walder, Alois ⁱ   Korger, Markus ^j   Schlögl, Ernst ^k   Sliwa, Tamer ^l   Wöll, Ernst ^m   Mitterer, Manfred ⁿ   Eisterer, Wolfgang ^a   Pober, Michael ^o   Gastl, Günther ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Klinikum Wels Grieskirchen GmbH   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^e KEPLER UNIVERSITY HOSPITAL   (Austria)

^f Landeskrankenhaus Feldkirch   (Austria)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h ELISABETHINEN HOSPITAL   (Austria)

ⁱ Aö Bezirkskrankenhaus Lienz ^*  (Austria)

^j KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^k HANUSCH HOSPITAL   (Austria)

^l Krankenhaus Hietzing   (Austria)

^m Krankenhaus St Vinzenz   (Austria)

ⁿ Krankenhaus Meran   (Italy)

^o Karl Landsteiner Institute for Implementation of Innovative Techniques in Cardiac Surgery   (Austria)

more..

Author keywords

CML; Outcome; Registry; Response; Treatment

Indexed keywords

BUSULFAN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; AUSTRIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH CARE MANAGEMENT; HUMAN; INCIDENCE; INFECTION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 78249280604     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1450-x     Document Type: Article

References (21)

1. JD Rowley 1973 Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 5405 290 293 1:STN:280:DyaE2c%2Fgs1eksw%3D%3D 10.1038/243290a0 4126434
2. Y Ben-Neriah GQ Daley AM Mes-Masson ON Witte D Baltimore 1986 The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene Science 233 4760 212 214 1:CAS:528:DyaL28XkvFagtrs%3D 10.1126/science. 3460176 3460176
3. RA Van Etten 2007 Oncogenic signaling: new insights and controversies from chronic myeloid leukemia J Exp Med 204 3 461 465 1:CAS:528: DC%2BD2sXjsVyrurc%3D 10.1084/jem.20062335 17353369 (Pubitemid 46457069)
4. BJ Druker S Tamura E Buchdunger S Ohno GM Segal S Fanning, et al. 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 5 561 566 1:CAS:528:DyaK28Xislyhs70%3D 10.1038/nm0596-561 8616716 (Pubitemid 26151518)
5. BJ Druker CL Sawyers H Kantarjian DJ Resta SF Reese JM Ford, et al. 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 14 1038 1042 1:CAS:528: DC%2BD3MXivFGnu7o%3D 10.1056/NEJM200104053441402 11287973 (Pubitemid 32267973)
6. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford, et al. 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 14 1031 1037 1:CAS:528: DC%2BD3MXivFGnu70%3D 10.1056/NEJM200104053441401 11287972 (Pubitemid 32267972)
7. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 23 2408 2417 1:CAS:528:DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
8. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum, et al. 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 6 1809 1820 1:CAS:528:DC%2BD28Xpsl2isrc%3D 10.1182/blood-2006-02-005686 16709930 (Pubitemid 44394987)
9. P Valent T Lion D Wolf C Sillaber H Agis A Petzer, et al. 2008 Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform Wien Klin Wochenschr 120 21-22 697 709 1:CAS:528:DC%2BD1MXjvFOktw%3D%3D 10.1007/s00508-008-1100-8 19116712
10. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum, et al. 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 6 1809 1820 1:CAS:528:DC%2BD28Xpsl2isrc%3D 10.1182/blood-2006-02-005686 16709930 (Pubitemid 44394987)
11. M Baccarani J Cortes F Pane D Niederwieser G Saglio J Apperley, et al. 2009 Chronic myeloid leukemia: an update of concepts and management recommendations of European leukemiaNet J Clin Oncol 27 35 6041 6051 1:CAS:528:DC%2BC3cXhtVWisLY%3D 10.1200/JCO.2009.25.0779 19884523
12. CM Lucas L Wang GM Austin K Knight SJ Watmough KH Shwe, et al. 2008 A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials Leukemia 22 10 1963 1966 1:CAS:528: DC%2BD1cXht1Cms7%2FJ 10.1038/leu.2008.225 18754023
13. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes, et al. 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 11 994 1004 10.1056/NEJMoa022457 12637609 (Pubitemid 36302244)
14. H de Lavallade JF Apperley JS Khorashad D Milojkovic AG Reid M Bua, et al. 2008 Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 20 3358 3363 10.1200/JCO.2007.15.8154 18519952
15. HM Kantarjian F Giles N Gattermann K Bhalla G Alimena F Palandri, et al. 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 10 3540 3546 1:CAS:528:DC%2BD2sXhtlarur3P 10.1182/blood-2007-03-080689 17715389 (Pubitemid 350159618)
16. A Hochhaus M Baccarani M Deininger JF Apperley JH Lipton SL Goldberg, et al. 2008 Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 6 1200 1206 1:CAS:528:DC%2BD1cXntVCjurw%3D 10.1038/leu.2008.84 18401416 (Pubitemid 351833788)
17. JE Sokal 1987 Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment Baillieres Clin Hematol 1 4 907 929 1:STN:280: DyaL1M%2Fmt1OrsQ%3D%3D 10.1016/S0950-3536(87)80032-X
18. M Usman NN Syed GN Kakepoto SN Adil M Khurshid 2007 Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response J Assoc Physicians India 55 103 107 1:STN:280:DC%2BD2szlvVyhsw%3D%3D 17571738
19. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 23 2408 2417 1:CAS:528:DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
20. A Hochhaus SG O'Brien F Guilhot BJ Druker S Branford L Foroni, et al. 2009 Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 6 1054 1061 1:CAS:528:DC%2BD1MXntFygt7w%3D 10.1038/leu.2009.38 19282833
21. O'Brien S, et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract #186